Adlai Nortye (NASDAQ:ANL) Director Ping Ji Sells 5,000 Shares

by · The Markets Daily

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL – Get Free Report) Director Ping Ji sold 5,000 shares of Adlai Nortye stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $16.63, for a total value of $83,150.00. Following the completion of the transaction, the director owned 131,667 shares of the company’s stock, valued at approximately $2,189,622.21. This trade represents a 3.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Adlai Nortye Trading Down 2.0%

Shares of NASDAQ ANL traded down $0.32 during trading hours on Thursday, hitting $15.43. 66,283 shares of the company traded hands, compared to its average volume of 372,919. The company has a debt-to-equity ratio of 0.04, a quick ratio of 0.65 and a current ratio of 9.55. The company’s 50 day moving average price is $13.89 and its 200 day moving average price is $11.96. Adlai Nortye Ltd. Sponsored ADR has a 12 month low of $0.88 and a 12 month high of $17.25.

Analyst Upgrades and Downgrades

ANL has been the topic of several recent analyst reports. Jefferies Financial Group started coverage on shares of Adlai Nortye in a research note on Thursday, September 10th. They issued a “buy” rating and a $31.00 target price on the stock. Wall Street Zen downgraded shares of Adlai Nortye from a “buy” rating to a “hold” rating in a report on Saturday, September 12th. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Adlai Nortye in a research report on Tuesday, September 8th. Cantor Fitzgerald began coverage on Adlai Nortye in a research report on Monday, June 22nd. They set an “overweight” rating for the company. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Adlai Nortye in a report on Tuesday, July 14th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Adlai Nortye has a consensus rating of “Moderate Buy” and an average price target of $29.50.

Read Our Latest Research Report on ANL

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. SmartHarvest Portfolios LLC grew its holdings in Adlai Nortye by 8.5% during the 1st quarter. SmartHarvest Portfolios LLC now owns 16,367 shares of the company’s stock worth $113,000 after acquiring an additional 1,279 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in Adlai Nortye during the first quarter worth $457,000. Seven Fleet Capital Management LP purchased a new stake in shares of Adlai Nortye during the second quarter valued at approximately $1,302,000. ADAR1 Capital Management LLC acquired a new position in Adlai Nortye during the first quarter worth approximately $816,000. Finally, Affinity Asset Advisors LLC acquired a new stake in shares of Adlai Nortye in the first quarter valued at $1,140,000. Hedge funds and other institutional investors own 35.21% of the company’s stock.

Adlai Nortye Company Profile

(Get Free Report)

Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases. The company’s research and development activities center on oncology and immuno-oncology, with the goal of addressing unmet needs in the treatment of solid tumors.

Adlai Nortye’s lead candidate is buparlisib, also known as AN2025, an oral pan-class I phosphoinositide 3-kinase (PI3K) inhibitor being developed for oncology indications, including head and neck cancer.

Further Reading